CYTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Cytokinetics's Capital Expenditure for the three months ended in Dec. 2023 was $-0.08 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-74.04 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Cytokinetics's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytokinetics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | 1.24 | - | - | - |
Cytokinetics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cytokinetics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cytokinetics's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cytokinetics's Capex-to-Operating-Cash-Flow falls into.
Cytokinetics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-1.416) | / | -414.333 | |
= | N/A |
Cytokinetics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.077) | / | -74.037 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytokinetics (NAS:CYTK) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Cytokinetics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert I Blum | officer: EVP, Corp. Development & CBO | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
John T Henderson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Fady Ibraham Malik | officer: SVP Research & Early Dev | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Muna Bhanji | director | C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Robert Wong | officer: VP, Chief Accounting Officer | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Ching Jaw | officer: SVP Finance & CFO | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Sandford D Smith | director | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
B Lynne Parshall | director | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Santo J Costa | director | |
Kaye Edward M. Md | director | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
Robert Arthur Harrington | director | C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Mark A Schlossberg | officer: SVP - Legal & General Counsel | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
David Cragg | officer: V.P., Human Resources | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
L Patrick Gage | director | C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044 |
From GuruFocus
By GuruFocus Research • 09-14-2023
By Marketwired • 10-02-2023
By Marketwired • 09-28-2023
By GuruFocus Research • 09-15-2023
By Marketwired • 10-06-2023
By Marketwired • 10-23-2023
By sperokesalga sperokesalga • 06-02-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 08-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.